Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.60
SQNM's Cash to Debt is ranked higher than
54% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. SQNM: 0.60 )
SQNM' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: 0.6

Equity to Asset -0.38
SQNM's Equity to Asset is ranked lower than
52% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SQNM: -0.38 )
SQNM' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.96
Current: -0.38

-0.48
0.96
F-Score: 4
Z-Score: -9.50
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -60.59
SQNM's Operating margin (%) is ranked higher than
72% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. SQNM: -60.59 )
SQNM' s 10-Year Operating margin (%) Range
Min: -11450   Max: -55.06
Current: -60.59

-11450
-55.06
Net-margin (%) -66.13
SQNM's Net-margin (%) is ranked higher than
71% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. SQNM: -66.13 )
SQNM' s 10-Year Net-margin (%) Range
Min: -10900   Max: -53.61
Current: -66.13

-10900
-53.61
ROA (%) -74.23
SQNM's ROA (%) is ranked higher than
55% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. SQNM: -74.23 )
SQNM' s 10-Year ROA (%) Range
Min: -134.79   Max: -17.89
Current: -74.23

-134.79
-17.89
ROC (Joel Greenblatt) (%) -370.61
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. SQNM: -370.61 )
SQNM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1096.39   Max: -256.41
Current: -370.61

-1096.39
-256.41
Revenue Growth (%) 28.80
SQNM's Revenue Growth (%) is ranked higher than
93% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SQNM: 28.80 )
SQNM' s 10-Year Revenue Growth (%) Range
Min: -20.6   Max: 293.1
Current: 28.8

-20.6
293.1
EBITDA Growth (%) -23.40
SQNM's EBITDA Growth (%) is ranked higher than
63% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. SQNM: -23.40 )
SQNM' s 10-Year EBITDA Growth (%) Range
Min: -57.8   Max: 45.4
Current: -23.4

-57.8
45.4
EPS Growth (%) -18.10
SQNM's EPS Growth (%) is ranked higher than
70% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. SQNM: -18.10 )
SQNM' s 10-Year EPS Growth (%) Range
Min: -59.3   Max: 43.7
Current: -18.1

-59.3
43.7
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SQNM Guru Trades in Q3 2013

Chuck Royce 676,000 sh (-46.18%)
Steven Cohen 2,100,000 sh (-48.16%)
» More
Q4 2013

SQNM Guru Trades in Q4 2013

Chuck Royce Sold Out
Steven Cohen Sold Out
» More
Q1 2014

SQNM Guru Trades in Q1 2014

Jim Simons 693,351 sh (New)
» More
Q2 2014

SQNM Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sequenom Inc

Gurus Hold Five-Year Lows in Biotech, Utilities
A rapid-research tool, the GuruFocus Five-Year Low Value Screen currently highlights three diverse U.S. companies on a five-year low, two of them held by billionaire investors, and two with high yields. Here are the company updates and trading highlights, as of June 30, 2013. Read more...

Ratios

vs
industry
vs
history
P/S 2.40
SQNM's P/S is ranked higher than
90% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. SQNM: 2.40 )
SQNM' s 10-Year P/S Range
Min: 0.99   Max: 29.2
Current: 2.4

0.99
29.2
Current Ratio 2.15
SQNM's Current Ratio is ranked higher than
59% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. SQNM: 2.15 )
SQNM' s 10-Year Current Ratio Range
Min: 1.15   Max: 26.12
Current: 2.15

1.15
26.12
Quick Ratio 2.04
SQNM's Quick Ratio is ranked higher than
62% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SQNM: 2.04 )
SQNM' s 10-Year Quick Ratio Range
Min: 0.94   Max: 26.03
Current: 2.04

0.94
26.03

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.50
SQNM's Price/Median PS Value is ranked higher than
90% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SQNM: 0.50 )
SQNM' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 36.02
Current: 0.5

0.23
36.02
Earnings Yield (Greenblatt) 551.50
SQNM's Earnings Yield (Greenblatt) is ranked higher than
94% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SQNM: 551.50 )
SQNM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 1271.1
Current: 551.5

0.9
1271.1
Forward Rate of Return (Yacktman) -31.50
SQNM's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. SQNM: -31.50 )
SQNM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 28.9
Current: -31.5

3.1
28.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QNMA.Germany
Sequenom, Inc., was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing innovative genetic analysis solutions to improve healthcare through its two operating segments: Molecular Diagnostics and Genetic Analysis. Molecular Diagnostics, in which Sequenom Center for Molecular Medicine, LLC or Sequenom CMM performs molecular diagnostic testing services utilizing its laboratory-developed tests (LDTs), which currently is focused on noninvasive prenatal and women's health related diagnostics and ophthalmology-related diagnostics, and plans to develop or acquire additional diagnostic tests in those and other fields including autoimmunity, neurology and oncology. Genetic Analysis segment researches, develops and commercializes components and applications for its proprietary Mass ARRAY system, a nucleic acid analysis research-use only system that measures genetic target material and variations. Product sales, services and contract research revenues from its Genetic Analysis segment are mainly derived from sales of its MassARRAY systems, which are comprised of hardware, software applications, consumable chips and reagents, as well as the provision of contract research services, to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions and government agencies. The Company faces competition from various companies developing and commercializing diagnostic assays, and from various companies researching and developing prenatal diagnostic technology, and from various companies offering nucleic acid analysis systems and services. Competitors and potential competitors include Ikonysis, Inc., Verinata Health, Inc. (a wholly owned subsidiary of Illumina, Inc.), Celula Inc., Kellbenx, Inc., Cellscape Corp., Fluidigm Corp., Ariosa Diagnostics, Inc., Natera, Beijing Genomics Institute, and others. In the United States, IVD tests may require either premarket approval, or PMA, or premarket notification, or 510(k) clearance, from the FDA prior to marketing in the United States. Regulation by governmental authorities in the United States and other countries will be a significant factor in the development, testing, production and marketing of diagnostic products, including tests that may be developed by it or its corporate partners, collaborators or licensees.
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 
3.31 Mar 12 2013 
Weekly CFO Buys Highlight: PTSX, MTG, IRDM, SQNM, FNFG, LF Aug 13 2012 
Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares Aug 03 2012 
Sequenom Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sequenom Inc. Reports Operating Results (10-Q) May 07 2010 
Sequenom Inc. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
SEQUENOM INC Financials Aug 08 2014
Sequenom, Inc. Announces Participation At The 2014 Wedbush Securities Life Sciences Management... Aug 05 2014
Sequenom, Inc. Announces Participation At The 2014 Wedbush Securities Life Sciences Management... Aug 05 2014
SEQUENOM INC Files SEC form 10-Q, Quarterly Report Aug 01 2014
SEQUENOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2014
Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 Jul 29 2014
Sequenom Enters Into License Agreement With Mayo Medical Laboratories Jul 29 2014
Q2 2014 Sequenom Earnings Release - After Market Close Jul 29 2014
Sequenom Laboratories Presents New Data on the Enhanced Sequencing Series for the MaterniT21™ Plus... Jul 22 2014
Sequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg Jul 21 2014
Sequenom Laboratories Expands International Noninvasive Prenatal Testing Services To Broader... Jul 21 2014
Sequenom, Inc. Announces Date Of Second Quarter 2014 Financial Results And Conference Call Jul 15 2014
Sequenom, Inc. Announces Date Of Second Quarter 2014 Financial Results And Conference Call Jul 15 2014
Sequenom resumed with a Buy at Jefferies Jul 03 2014
Sequenom: A Reversal Of Misfortune Jun 26 2014
BUZZ-U.S. Stocks on the Move-Arotech, Rockwell, Meritor Jun 23 2014
Nicox and Sequenom announce the launch of expanded access to RetnaGene™ test portfolio in the U.S. Jun 19 2014
Sequenom price target raised to $5 from $4 at Wedbush Jun 17 2014
Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% Jun 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide